Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKintara Therapeutics Inc

Kintara Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-11-14T21:00:24.392017Z
Market Cap
10.39M

Momentum Score

…

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.08
Low
5.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
6.30
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-329.00%
Net Debt
-1.53M
ROCE
-1650.61%
Diluted EPS TTM
-2.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -14.65M -22.66M -38.30M -9.13M -8.05M
Net income -14.65M -22.62M -38.32M -10.11M -7.41M
Selling general administrative 5.49M 7.51M 9.76M 4.51M 4.74M
Reconciled depreciation 0.06M 0.06M 0.03M 0.01M 0.02M
Ebit -14.81M -22.69M -21.67M -7.09M -8.69M
Ebitda -14.75M -22.63M -21.63M -7.08M -8.67M
Depreciation and amortization 0.06M 0.06M 0.03M 0.01M 0.02M
Operating income -14.81M -22.69M -21.67M -7.09M -8.69M
Other operating expenses 14.80M 22.68M 21.57M 8.14M 8.40M
Interest expense - 0.01M 0.03M 0.00M 0.00M
Interest income - - - 0.08M 0.06M
Net interest income 0.14M 0.01M -0.12M 0.08M 0.06M
Income tax expense -0.15M -0.04M 0.03M 0.98M -0.64M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 14.80M 22.68M 21.57M 8.14M 8.40M
Total other income expense net 0.01M 0.03M -16.63M -2.04M 0.64M
Net income from continuing ops -14.65M -22.66M -38.30M -9.13M -8.05M
Net income applicable to common shares -15.02M -25.13M -41.50M -9.13M -8.13M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 3.98M 15.95M 13.54M 2.94M 4.04M
Intangible assets - - - 0.00M 0.01M
Other current assets 0.66M 1.48M 1.26M 0.36M 0.28M
Total liab 3.25M 4.15M 2.96M 2.67M 2.07M
Total stockholder equity 0.73M 11.79M 10.58M 0.26M 1.97M
Deferred long term liab - - - 0.08M -
Other current liab 0.30M 0.72M 0.56M 0.66M 0.33M
Common stock 0.00M 0.07M 0.03M 0.01M 0.00M
Capital stock 10.65M 12.62M 14.96M 4.81M 4.98M
Retained earnings -151.38M -136.36M -111.22M -69.72M -60.58M
Other liab 0.17M 0.16M 0.18M - -
Other assets - - - 0.08M -
Cash 1.53M 11.78M 10.54M 2.39M 3.72M
Total current liabilities 3.08M 3.99M 2.78M 2.67M 2.07M
Net debt -1.53M -11.78M -10.54M -2.39M -3.72M
Other stockholder equity 141.44M 135.51M 106.82M 65.15M 57.54M
Property plant equipment 0.71M 0.09M 0.15M 0.00M -
Total current assets 3.27M 13.26M 11.79M 2.85M 4.03M
Net tangible assets -9.91M -0.76M -4.35M -4.54M -3.02M
Net receivables - - - 0.01M 0.03M
Inventory - - - 0.09M -
Accounts payable 2.78M 3.27M 2.22M 2.01M 1.74M
Accumulated other comprehensive income 0.02M 0.02M 0.02M 0.02M 0.02M
Common stock total equity - - 0.03M 8.62M 0.00M
Non currrent assets other - 2.60M 1.60M 0.00M 0.01M
Non current assets total 0.71M 2.69M 1.75M 0.09M 0.01M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.23M 0.00M 0.96M - 0.00M
Change to liabilities -0.44M 1.01M -0.07M 0.21M 0.20M
Total cashflows from investing activities -0.23M -0.23M 0.96M 0.96M 0.96M
Total cash from financing activities 1.85M 21.64M 26.04M 6.60M 4.07M
Change to operating activities -1.75M -1.06M -2.58M 0.28M 0.93M
Net income -14.65M -22.66M -38.30M -9.13M -8.05M
Change in cash -10.24M 1.24M 8.14M -1.33M -2.25M
Begin period cash flow 11.78M 10.54M 2.39M 3.72M 5.97M
End period cash flow 1.53M 11.78M 10.54M 2.39M 3.72M
Total cash from operating activities -11.87M -20.39M -18.86M -7.93M -6.33M
Issuance of capital stock 1.90M 21.57M 21.60M 6.58M 3.36M
Depreciation 0.06M 0.06M 0.03M 0.01M 0.02M
Dividends paid -0.01M -0.01M -0.01M -0.01M 0.01M
Other cashflows from financing activities -0.04M 0.07M 4.95M 0.03M 0.72M
Change to netincome 4.92M 2.26M 21.96M 0.70M 0.57M
Capital expenditures 0.23M 0.23M 0.01M 0.01M 0.01M
Change in working capital -2.19M -0.06M -2.65M 0.49M 1.13M
Stock based compensation 1.49M 2.25M 5.28M 0.49M 0.95M
Other non cash items 3.23M 0.02M 0.12M 0.01M 0.03M
Free cash flow -12.10M -20.39M -18.87M -7.93M -6.33M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Kintara Therapeutics Inc

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

9920 Pacific Heights Blvd, San Diego, CA, United States, 92121

858 350 4364

https://www.kintara.com

2

Name Title Year Born
Mr. Robert E. Hoffman B.B.A., CPA, CPA Pres, CEO & Chairman 1966
Dr. Dennis M. Brown B.Sc., M.A., Ph.D. Co-Founder & Chief Scientific Officer 1949
Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc CFO & Sec. 1967
Mr. Jeffrey A. Bacha B.Sc., M.B.A. Founder 1968
Mr. Greg A. Johnson Acting Head of Operations NA
Mr. Robert E. Hoffman B.B.A., CPA President, CEO, Interim CFO & Chairman of the Board 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…